Sponsored

Creso Pharma welcomes milestone developments by acquisition target Halucenex

Source: Have a nice day Photo, Shutterstock

Summary

  • Halucenex and Growing Together Research (GTR) have entered into an advisory agreement to explore genome sequencing of magic mushrooms.
  • The deal would help Halucenex generate an IP portfolio to maximise the active ingredients in different mushroom strains. 
  • Halucenex will expand its product portfolio into additional psychedelic substances.
  • Creso Pharma highlighted that due diligence on the Halucenex acquisition is progressing smoothly.

Creso Pharma Limited (ASX:CPH, FRA:1X8) has updated the market with significant announcements related to its target acquisition company, Halucenex Life Sciences.

International cannabis player Creso Pharma is engaged in developing and selling cannabis-based products worldwide. The Company forms an essential cog in the wheel of the growing Australian cannabis industry with other players like Althea Group Holdings Limited (ASX:AGH), Bod Australia Limited (ASX:BDA), MGC Pharmaceuticals Ltd (ASX:MXC), and AusCann Group Holdings Ltd (ASX:AC8).

In the latest update, the company has zeroed in on the two crucial developments by Halucenex, as shown in the illustration below:

ALSO READ: Creso Pharma aims to make inroads in US cannabis space with latest appointment

Let us dive deeper and discuss the key achievements of Halucenex-

Advisory agreement with GTR

On 12 April 2021, Creso Pharma announced that Halucenex had signed an advisory agreement with US-based Growing Together Research (GTR). The deal would help Halucenex generate intellectual property (IP) portfolio to maximise the active ingredients in several strains of magic mushrooms.

Halucenex will also assess the efficacy of elements and conclude which are the best ones to treat certain conditions.

After receiving the Dealer Licence amendment, both parties will emphasise on sequencing and analysing the psychedelic mushrooms’ genomes, primarily the Psilocybe cubensis strain.

Further, Halucenex will be engaged in generating an entire set of Psilocybe cubensis phenotypes, which will be tailored to specific use cases. The Company highlighted that this would include:

  • Extraction of compounds from a fungal biomass standpoint and,
  • A holistic organism to offer whole mushrooms to medical professionals to administer in a standardised format.

Initial data from sequencing is anticipated to assist Halucenex in the treatment development initiatives and generating higher yield from extraction and cultivation.

ALSO READ: Creso beefs up Canadian business as Mernova secures new POs, product launches

GTR in a nutshell:

  • Growing Together Research is a US-based biotechnology player that was founded in 2017.
  • GTR specialises in computational genomics and bioengineering.
  • The Company has focused on exploring the potential of the Cannabis sativa (hemp) organism.
  • GTR is made up of a leading, multi-disciplinary team of geneticists, computer scientists and bioinformatics specialists who will assist Halucenex with several objectives.

Halucenex to expand its R&D programs

The Company also advised that Halucenex will expand its research and development (R&D) initiatives and foray into additional psychedelic substances such as Ketamine, LSD, and MDMA.

This expansion will focus on using these substances to treat mental health conditions, including Post Traumatic Stress Disorder (PTSD), treatment-resistant depression and other mental health illnesses. This expansion will considerably widen the potential opportunities for Halucenex. The portfolio extension will occur after the receipt of the amended Dealer Licence of the Company.

The Company anticipates that this pleasing development will underpin future product development initiatives of Halucenex.

Additional initiatives related to the clinical trials will also add to the increasing evidence to use psychedelic compounds for specific mental health conditions.

Currently, Halucenex is exploring programs to utilise additional psychedelic substances at its treatment facility in Nova Scotia, Canada.

DID YOU KNOW: Creso Pharma rolls out new hemp tea products using revolutionary technology

Management Commentary

Adam Blumenthal, Non-executive Chairman of Creso Pharma, stated that Halucenex continues to achieve several key milestones, laying a robust foundation in its clinical trial schedule and future treatment development initiatives.

Mr Blumenthal further added:

Adding to this, Bill Fleming, Founder & CEO of Halucenex, added-

He also added once it is known which strains work best for which disorder or addiction, these strains will be sequenced, and the Company would be able to optimise its growth to fulfil the rising demand for an alternative treatment.

Meanwhile, Creso Pharma also updated that the due diligence on the Halucenex acquisition is progressing positively.

On 14 April 2021, CPH shares were trading at AU$0.197 (at AEST 3:17 PM).


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK